Understanding reliever overuse in patients purchasing over-the-counter short-acting beta2 agonists: an Australian community pharmacy-based survey

Elizabeth A Azzi (Corresponding Author), Vicky Kritikos, Matthew J Peters, David B Price, Pamela Srour, Biljana Cvetkovski, Sinthia Bosnic-Anticevich

Research output: Contribution to journalArticle

1 Downloads (Pure)

Abstract

OBJECTIVES: Overuse of asthma relievers is associated with significant adverse consequences. This study aimed to better understand the population purchasing and using short-acting beta agonists (SABA) over the counter (OTC); and compare the demographic, clinical and behavioural characteristics of those who overuse SABA with those who do not.

DESIGN AND SETTING: Real-world cross-sectional observational study in community pharmacy.

PARTICIPANTS: Of 412 participants ≥16 years requesting SABA OTC, 289 were SABA overusers (used SABA more than twice per week in the past 4 weeks).

MAIN OUTCOME MEASURE: Reliever use, Global Initiative for Asthma-defined control, healthcare utilisation, patterns of preventer use.

RESULTS: 70.1% of participants were classified as SABA overusers, that is, reporting SABA use more than twice a week within the last 4 weeks, 73.6% reported not using a preventer daily and only 81.6% reported a doctor diagnosis of asthma. SABA overusers were more likely to have moderate-severe nasal symptoms (80.8% vs 63.0%, p<0.001) and a diagnosis of depression (11.1% vs 5.7%, p<0.001), when compared with SABA non-overusers. A higher proportion of SABA overusers had uncontrolled asthma (59.0% vs 15.4%, p<0.001), were more likely to use oral corticosteroids to manage worsening asthma symptoms (26.2% vs 13.5%, p<0.01) and visit the doctor for their asthma in the past 12 months (74.5% vs 62.5%, p<0.01), when compared to SABA non-overusers.

CONCLUSIONS: This study uncovers a hidden population of people who can only be identified in pharmacy with suboptimal asthma, coexisting rhinitis, poor preventer adherence and, in some cases, no asthma diagnosis.

Original languageEnglish
Article numbere028995
Number of pages11
JournalBMJ Open
Volume9
Issue number8
Early online date14 Aug 2019
DOIs
Publication statusPublished - 14 Aug 2019

Fingerprint

Pharmacies
Asthma
Surveys and Questionnaires
Rhinitis
Nose
Population
Observational Studies
Adrenal Cortex Hormones
Cross-Sectional Studies
Demography
Delivery of Health Care

Keywords

  • asthma
  • chronic airways disease
  • respiratory medicine (see thoracic medicine)

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Understanding reliever overuse in patients purchasing over-the-counter short-acting beta2 agonists : an Australian community pharmacy-based survey. / Azzi, Elizabeth A (Corresponding Author); Kritikos, Vicky; Peters, Matthew J; Price, David B; Srour, Pamela; Cvetkovski, Biljana; Bosnic-Anticevich, Sinthia.

In: BMJ Open, Vol. 9, No. 8, e028995, 14.08.2019.

Research output: Contribution to journalArticle

Azzi, Elizabeth A ; Kritikos, Vicky ; Peters, Matthew J ; Price, David B ; Srour, Pamela ; Cvetkovski, Biljana ; Bosnic-Anticevich, Sinthia. / Understanding reliever overuse in patients purchasing over-the-counter short-acting beta2 agonists : an Australian community pharmacy-based survey. In: BMJ Open. 2019 ; Vol. 9, No. 8.
@article{a54fd164a51740d49aebb8f83c152d7e,
title = "Understanding reliever overuse in patients purchasing over-the-counter short-acting beta2 agonists: an Australian community pharmacy-based survey",
abstract = "OBJECTIVES: Overuse of asthma relievers is associated with significant adverse consequences. This study aimed to better understand the population purchasing and using short-acting beta agonists (SABA) over the counter (OTC); and compare the demographic, clinical and behavioural characteristics of those who overuse SABA with those who do not.DESIGN AND SETTING: Real-world cross-sectional observational study in community pharmacy.PARTICIPANTS: Of 412 participants ≥16 years requesting SABA OTC, 289 were SABA overusers (used SABA more than twice per week in the past 4 weeks).MAIN OUTCOME MEASURE: Reliever use, Global Initiative for Asthma-defined control, healthcare utilisation, patterns of preventer use.RESULTS: 70.1{\%} of participants were classified as SABA overusers, that is, reporting SABA use more than twice a week within the last 4 weeks, 73.6{\%} reported not using a preventer daily and only 81.6{\%} reported a doctor diagnosis of asthma. SABA overusers were more likely to have moderate-severe nasal symptoms (80.8{\%} vs 63.0{\%}, p<0.001) and a diagnosis of depression (11.1{\%} vs 5.7{\%}, p<0.001), when compared with SABA non-overusers. A higher proportion of SABA overusers had uncontrolled asthma (59.0{\%} vs 15.4{\%}, p<0.001), were more likely to use oral corticosteroids to manage worsening asthma symptoms (26.2{\%} vs 13.5{\%}, p<0.01) and visit the doctor for their asthma in the past 12 months (74.5{\%} vs 62.5{\%}, p<0.01), when compared to SABA non-overusers.CONCLUSIONS: This study uncovers a hidden population of people who can only be identified in pharmacy with suboptimal asthma, coexisting rhinitis, poor preventer adherence and, in some cases, no asthma diagnosis.",
keywords = "asthma, chronic airways disease, respiratory medicine (see thoracic medicine)",
author = "Azzi, {Elizabeth A} and Vicky Kritikos and Peters, {Matthew J} and Price, {David B} and Pamela Srour and Biljana Cvetkovski and Sinthia Bosnic-Anticevich",
year = "2019",
month = "8",
day = "14",
doi = "10.1136/bmjopen-2019-028995",
language = "English",
volume = "9",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "8",

}

TY - JOUR

T1 - Understanding reliever overuse in patients purchasing over-the-counter short-acting beta2 agonists

T2 - an Australian community pharmacy-based survey

AU - Azzi, Elizabeth A

AU - Kritikos, Vicky

AU - Peters, Matthew J

AU - Price, David B

AU - Srour, Pamela

AU - Cvetkovski, Biljana

AU - Bosnic-Anticevich, Sinthia

PY - 2019/8/14

Y1 - 2019/8/14

N2 - OBJECTIVES: Overuse of asthma relievers is associated with significant adverse consequences. This study aimed to better understand the population purchasing and using short-acting beta agonists (SABA) over the counter (OTC); and compare the demographic, clinical and behavioural characteristics of those who overuse SABA with those who do not.DESIGN AND SETTING: Real-world cross-sectional observational study in community pharmacy.PARTICIPANTS: Of 412 participants ≥16 years requesting SABA OTC, 289 were SABA overusers (used SABA more than twice per week in the past 4 weeks).MAIN OUTCOME MEASURE: Reliever use, Global Initiative for Asthma-defined control, healthcare utilisation, patterns of preventer use.RESULTS: 70.1% of participants were classified as SABA overusers, that is, reporting SABA use more than twice a week within the last 4 weeks, 73.6% reported not using a preventer daily and only 81.6% reported a doctor diagnosis of asthma. SABA overusers were more likely to have moderate-severe nasal symptoms (80.8% vs 63.0%, p<0.001) and a diagnosis of depression (11.1% vs 5.7%, p<0.001), when compared with SABA non-overusers. A higher proportion of SABA overusers had uncontrolled asthma (59.0% vs 15.4%, p<0.001), were more likely to use oral corticosteroids to manage worsening asthma symptoms (26.2% vs 13.5%, p<0.01) and visit the doctor for their asthma in the past 12 months (74.5% vs 62.5%, p<0.01), when compared to SABA non-overusers.CONCLUSIONS: This study uncovers a hidden population of people who can only be identified in pharmacy with suboptimal asthma, coexisting rhinitis, poor preventer adherence and, in some cases, no asthma diagnosis.

AB - OBJECTIVES: Overuse of asthma relievers is associated with significant adverse consequences. This study aimed to better understand the population purchasing and using short-acting beta agonists (SABA) over the counter (OTC); and compare the demographic, clinical and behavioural characteristics of those who overuse SABA with those who do not.DESIGN AND SETTING: Real-world cross-sectional observational study in community pharmacy.PARTICIPANTS: Of 412 participants ≥16 years requesting SABA OTC, 289 were SABA overusers (used SABA more than twice per week in the past 4 weeks).MAIN OUTCOME MEASURE: Reliever use, Global Initiative for Asthma-defined control, healthcare utilisation, patterns of preventer use.RESULTS: 70.1% of participants were classified as SABA overusers, that is, reporting SABA use more than twice a week within the last 4 weeks, 73.6% reported not using a preventer daily and only 81.6% reported a doctor diagnosis of asthma. SABA overusers were more likely to have moderate-severe nasal symptoms (80.8% vs 63.0%, p<0.001) and a diagnosis of depression (11.1% vs 5.7%, p<0.001), when compared with SABA non-overusers. A higher proportion of SABA overusers had uncontrolled asthma (59.0% vs 15.4%, p<0.001), were more likely to use oral corticosteroids to manage worsening asthma symptoms (26.2% vs 13.5%, p<0.01) and visit the doctor for their asthma in the past 12 months (74.5% vs 62.5%, p<0.01), when compared to SABA non-overusers.CONCLUSIONS: This study uncovers a hidden population of people who can only be identified in pharmacy with suboptimal asthma, coexisting rhinitis, poor preventer adherence and, in some cases, no asthma diagnosis.

KW - asthma

KW - chronic airways disease

KW - respiratory medicine (see thoracic medicine)

UR - http://www.scopus.com/inward/record.url?scp=85070779906&partnerID=8YFLogxK

UR - http://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2019-028995

UR - http://www.mendeley.com/research/understanding-reliever-overuse-patients-purchasing-overthecounter-shortacting-beta-sub2sub-agonists

UR - http://www.mendeley.com/research/understanding-reliever-overuse-patients-purchasing-overthecounter-shortacting-beta-2-agonists-austra

U2 - 10.1136/bmjopen-2019-028995

DO - 10.1136/bmjopen-2019-028995

M3 - Article

C2 - 31412998

VL - 9

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 8

M1 - e028995

ER -